Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute mye… Read more
Market Cap & Net Worth: Syros Pharmaceuticals Inc (SYRS)
Syros Pharmaceuticals Inc (NASDAQ:SYRS) has a market capitalization of $638.61K ($638.61K) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #38294 globally and #12463 in its home market, demonstrating a -23.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Syros Pharmaceuticals Inc's stock price $0.02 by its total outstanding shares 26832500 (26.83 Million).
Syros Pharmaceuticals Inc Market Cap History: 2016 to 2025
Syros Pharmaceuticals Inc's market capitalization history from 2016 to 2025. Data shows change from $3.26 Billion to $638.61K (-63.93% CAGR).
Syros Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Syros Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
21.04x
Syros Pharmaceuticals Inc's market cap is 21.04 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.26 Billion | $317.00K | -$47.74 Million | 10292.85x | N/A |
| 2017 | $2.61 Billion | $1.10 Million | -$54.01 Million | 2371.30x | N/A |
| 2018 | $1.49 Billion | $2.05 Million | -$62.28 Million | 729.06x | N/A |
| 2019 | $1.85 Billion | $1.98 Million | -$75.44 Million | 935.48x | N/A |
| 2020 | $2.91 Billion | $15.09 Million | -$85.83 Million | 192.89x | N/A |
| 2021 | $874.74 Million | $23.49 Million | -$90.47 Million | 37.24x | N/A |
| 2022 | $96.33 Million | $14.88 Million | -$49.30 Million | 6.47x | N/A |
| 2023 | $209.03 Million | $9.94 Million | -$164.57 Million | 21.04x | N/A |
Competitor Companies of SYRS by Market Capitalization
Companies near Syros Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Syros Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Syros Pharmaceuticals Inc Historical Marketcap From 2016 to 2025
Between 2016 and today, Syros Pharmaceuticals Inc's market cap moved from $3.26 Billion to $ 638.61K, with a yearly change of -63.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $638.61K | -89.64% |
| 2024 | $6.17 Million | -97.05% |
| 2023 | $209.03 Million | +116.99% |
| 2022 | $96.33 Million | -88.99% |
| 2021 | $874.74 Million | -69.95% |
| 2020 | $2.91 Billion | +57.02% |
| 2019 | $1.85 Billion | +24.06% |
| 2018 | $1.49 Billion | -42.75% |
| 2017 | $2.61 Billion | -19.98% |
| 2016 | $3.26 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Syros Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $638.61K USD |
| MoneyControl | $638.61K USD |
| MarketWatch | $638.61K USD |
| marketcap.company | $638.61K USD |
| Reuters | $638.61K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.